View all

Briefings in English - 2008

Class actions in the EU: a threat to the life sciences industry?

Article written by Jonathan Isted, Nicolai Goeke and Mira Raja, originally published in PLC Cross-border Life Sciences Handbook 2008/09. (December 2008)

ECJ ruling on pharmaceuticals supply restrictions

The European Court of Justice has indicated limits that dominant companies must observe when taking measures to restrict parallel trade. The judgment provides important guidance to the pharmaceuticals sector and emphasises the continuing importance of the single market integration aim in the interpretation of EU competition law. (September 2008)

Briefings in English - 2007

Life sciences in China: future developments

What future developments are expected in the regulation of medicinal products, patent and trade mark law, and product liability? (April 2007)

Life sciences in China: intro

This pack provides an overview of the legal landscape in which both domestic and foreign players in this sector operate.We look at the regulatory environment; rules regarding pricing, marketing, advertising and packaging; patent and trade mark law; product liability law; and future developments of note. (April 2007)

Life sciences in China: marketing issues

How does the authorisation process work? (April 2007)

Life sciences in China: patents

what are the criteria for patentability? (April 2007)

Life sciences in China: product liability issues

What are the relevant product liability laws? (April 2007)

Life sciences in China: regulatory issues

How is the national healthcare system structured and funded? (April 2007)

Life sciences in China: trade marks

Can product brands be protected by registration as a trade mark? If so, what is the test for obtaining trade mark protection? (April 2007)

Life sciences: advertising, packaging and pricing issues

Life sciences in China: advertising, packaging and pricing issues. (April 2007)

Briefings in English - 2006

Restrictions on parallel trade – a change in direction?

The European Commission has traditionally been hostile to distribution arrangements that limit parallel trade. It has taken the view that agreements incorporating these restraints have as their 'object' the restriction of competition and therefore automatically infringe article 81(1); and that such agreements are most unlikely to satisfy the conditions for exemption under article 81(3). In its judgment in GlaxoSmithKline Services Unlimited v Commission on 27 September 2006, the EC Court of First Instance (CFI) called the making of such 'quick' assumptions into question, at least in the context of agreements operating in the pharmaceuticals sector. (October 2006)

For information on the different formats of our publications, please view our accessibility page.

Search publications

News

Freshfields advises Wyeth Pharmaceuticals on its acquisition of Thiakis Limited View

Textbooks

Books produced by/ in association with the firm

Contact